Clopidogrel
Unchecked
From Pharmacopedia
More actions
Clopidogrel
Plavix
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Acute coronary syndrome (with aspirin)0, Post-PCI dual antiplatelet therapy0, Secondary stroke prevention0, Peripheral arterial disease0
Pharmacy
Starting dose
75 mg PO once daily for maintenance; 300-600 mg PO loading dose in ACS or before PCI
Preparations
75 mg, 300 mg tablets
US FDA Max
75 mg/d maintenance (loading doses are single events)
Pharmacology
Routes
Oral
Onset
Antiplatelet effect within 2 hours of a loading dose; steady-state at 5-7 days of maintenance dosing
Duration
5-7 days (platelet lifespan; irreversible receptor binding)
Half-life
~6 hours (parent); active metabolite very short-lived but produces irreversible platelet effect[2]
Bioavailability
~50% (oral)[2]
Pregnancy
Limited data; weigh against alternatives (aspirin) where feasible.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Clopidogrel is a prodrug; CYP2C19 (primary) plus CYP3A4 and others bioactivate it to an unstable thiol metabolite that covalently and irreversibly binds the platelet P2Y12 ADP receptor, blocking ADP-mediated platelet activation, GPIIb/IIIa expression, and aggregation for the platelet's lifespan.0 CYP2C19 polymorphism is one of the most clinically actionable pharmacogenomic interactions in current cardiology: poor metabolizers generate insufficient active drug and have demonstrably worse outcomes after PCI; CPIC guidelines support alternative-agent therapy (prasugrel or ticagrelor) in those genotypes[1].
References
edit- ↑ CPIC Guideline for CYP2C19 and Clopidogrel, 2022. https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/
- ↑ 2.0 2.1 FDA Prescribing Information, Plavix (clopidogrel bisulfate), Sanofi/Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020839s062lbl.pdf